CN105999224B - A kind of biomimetic type gynaecologic washing lotion and preparation method thereof - Google Patents
A kind of biomimetic type gynaecologic washing lotion and preparation method thereof Download PDFInfo
- Publication number
- CN105999224B CN105999224B CN201610316286.3A CN201610316286A CN105999224B CN 105999224 B CN105999224 B CN 105999224B CN 201610316286 A CN201610316286 A CN 201610316286A CN 105999224 B CN105999224 B CN 105999224B
- Authority
- CN
- China
- Prior art keywords
- washing lotion
- vagina
- biomimetic type
- gynaecologic washing
- manual simulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000005406 washing Methods 0.000 title claims abstract description 52
- 239000006210 lotion Substances 0.000 title claims abstract description 51
- 230000003592 biomimetic effect Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 210000001215 vagina Anatomy 0.000 claims abstract description 60
- 230000003115 biocidal effect Effects 0.000 claims abstract description 23
- 210000003756 cervix mucus Anatomy 0.000 claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 22
- 241000257159 Musca domestica Species 0.000 claims abstract description 21
- 238000004088 simulation Methods 0.000 claims abstract description 20
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 19
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 17
- 230000033228 biological regulation Effects 0.000 claims abstract description 10
- 239000012634 fragment Substances 0.000 claims description 34
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 23
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 15
- 239000004202 carbamide Substances 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000007836 KH2PO4 Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 11
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 11
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 11
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 239000001103 potassium chloride Substances 0.000 claims description 10
- 238000009418 renovation Methods 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 8
- 239000001110 calcium chloride Substances 0.000 claims description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 8
- 229940039696 lactobacillus Drugs 0.000 claims description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 229910052564 epsomite Inorganic materials 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 abstract description 23
- 201000008100 Vaginitis Diseases 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 9
- 230000003749 cleanliness Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 31
- 230000000052 comparative effect Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 241000186000 Bifidobacterium Species 0.000 description 9
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 9
- 241000193830 Bacillus <bacterium> Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001502500 Trichomonadida Species 0.000 description 6
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 6
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 6
- 210000003905 vulva Anatomy 0.000 description 6
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 5
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 241000224527 Trichomonas vaginalis Species 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 229940116978 human epidermal growth factor Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 239000006916 nutrient agar Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102400001107 Secretory component Human genes 0.000 description 2
- 206010071212 Vulvovaginal injury Diseases 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006481 glucose medium Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940063190 flagyl Drugs 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002558 medical inspection Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to personal cleanliness's articles for use field, specifically related to a kind of biomimetic type gynaecologic washing lotion and preparation method thereof, the gynaecologic washing lotion includes manual simulation's vaginal secretion that house fly antibiotic peptide, xylo-oligosaccharide, xanthans and pH are 3.3~4.8, and the content of the house fly antibiotic peptide, xylo-oligosaccharide and xanthans in manual simulation's vaginal secretion is respectively 0.1~10.0g/L, 5~10.0g/L and 0.05~0.15g/L.The invention provides a kind of biomimetic type gynaecologic washing lotion with sterilized, regulation vaginal flora and reparation vagina function, it has significant curative effect to different types of vaginitis.
Description
Technical field
The invention belongs to personal cleanliness's articles for use field, and in particular to a kind of biomimetic type gynaecologic washing lotion and preparation method thereof.
Background technology
Vaginitis is the inflammation of connective tissue under vagina mucosa and mucous membrane, is the most common disease of gynaecology.Normal health
Women, due to anatomy and biochemical characteristics, intrusion of the vagina to pathogen has natural defense function, when preventing naturally for vagina
Imperial function is destroyed, then pathogen can take advantage of the occasion to invade, and cause the generation of colpitis.According to statistics, China's Status of Married Child-bearing aged Women
In there is more than 80% to be annoying by this disease is light or heavy.
Vaginitis causes mainly due to the flora imbalance of intravaginal, i.e., normally colonize in the microecological balance of intravaginal
(flora) is lacked of proper care, and the beneficial bacterium such as ability of Lactobacillus in human vagina is reduced and other bacterium amount reproductions, and anaerobic bacteria breeding produces amine simultaneously
Class material, alkalize vagina, increases vaginal fluid and has stink.Therefore the normal vaginal flora balance of regulation patient is prevention
With the key for the treatment of vaginitis.
At present, the product for the treatment of vaginitis is mainly based on sterilization, one side common antibiotics and various with antibacterial
The washing lotion of effect.So while pathogenic microorganisms is killed, leading flora (Bacillus acidi lactici, vagina bifid bar have also been killed
Bacterium), although symptom has been alleviated during medication, once being discontinued other miscellaneous bacterias quickly and can grow rapidly, makes inflammation alternately and repeatedly
Occur.Long-term use antibiotic, antimicrobial can also make various pathogen produce drug resistance, and the flora for aggravating intravaginal is unbalance.Separately
On the one hand, existing washing lotion constitutes entirely different with vaginal secretion, and lavation vagina can accelerate the aging of vagina repeatedly, easily make
Vaginal dryness.
Chinese patent application 201310062784.6 discloses a kind of bionic gynecologic care solution and preparation method thereof, described
Gynecologic care solution includes the artificial vagina juice of antibacterial peptide and pH 3.3~4.4, and the antibacterial peptide is in artificial vagina juice
In content be 0.1~10.0g/L；The artificial vagina juice includes artificial body fluid and thickener, and the thickener is in institute
It is 0.5~5.0g/L to state the content in artificial body fluid.The invention bionic gynecologic care solution uses Bionic Design, with prosthesis
Liquid adds thickener and adjusts its viscosity as solvent, with its pH value of acid-base accommodation, obtain with the vaginal secretion of human body into
Point, the close artificial vagina juice of viscosity, pH, then do not have chemical bactericide chronic as bactericide from antibacterial peptide
The drawbacks of corroding vagina viscosity, will not excessively change the physiological equilibrium of vaginal microenvironment and destruction vagina, can be used to treat obstinate
Property vaginitis and daily vagina health care diseases prevention.Applicant is it has been investigated that the product has the following disadvantages：1. it is due to prosthesis
The hypersaline environment of liquid reduces the bioactivity of antibacterial peptide, ultimately results in its anti-microbe ability and is obviously reduced；2. it is that this is artificial
The composition of body fluid and human vagina's juice still has larger difference, is not truly bionical, therefore itself and the moon
Road compatibility is poor；3. it is the main purpose that treatment vaginitis is reached to kill vagina harmful bacteria of the product, but it is to vagina
The effect that flora is not balanced, and it can not repair the infringement that vaginitis is caused to vagina, therefore cause vaginitis easily multiple
Hair, the crowd for having vaginitis medical history is still the group of people at high risk of vaginitis；4. it is because washing lotion is shorter in the intravaginal residence time
Cause antibacterial peptide action time too short, therefore need to repeat lavation vagina in order to reach preferable antibacterial effect, when using every time,
Multiple relation is easily destroyed vagina inside microenvironment.
Therefore, it is necessary to develop a kind of biomimetic type gynaecology with sterilized, regulation vaginal flora, reparation vagina function wash
Liquid.
The content of the invention
Defect it is an object of the invention to overcome above-mentioned prior art, there is provided one kind has sterilized, regulation vaginal flora
With the biomimetic type gynaecologic washing lotion for repairing vagina function, it has significant curative effect to different types of vaginitis.
It is the invention provides a kind of biomimetic type gynaecologic washing lotion, including house fly antibiotic peptide, xylo-oligosaccharide, xanthans and pH
3.3~4.8 manual simulation's vaginal secretion, the house fly antibiotic peptide, xylo-oligosaccharide and xanthans are in manual simulation's vagina
Content in juice is respectively 0.1~10.0g/L, 5~10.0g/L and 0.05~0.15g/L.
Preferably, the content of the house fly antibiotic peptide, xylo-oligosaccharide and xanthans in manual simulation's vaginal secretion
Respectively 0.1g/L, 6.0g/L and 0.1g/L.
Preferably, manual simulation's vaginal secretion is composed of the following components：5~10g/L of NaCl, KC l 0.3~
0.5g/L、CaClZ0.1~0.2g/L, NaHCO30.3~0.45g/L, MgCl2·6H20.006~0.015g/L of O,
MgSO4·7H20.04~0.08g/L of O, KH2PO40.05~0.08g/L, Na2HPO4·12H20.05~0.08g/L of O, Portugal
0.1~2.5g/L of grape sugar, 0.5~3g/L of urea, 0.001~0.003g/L of gram positive bacterial cell fragment and surplus are gone
Ionized water.
Preferably, manual simulation's vaginal secretion is composed of the following components：NaCl 8.0g/L、KCl 0.45g/L、
CaCl2 0.15g/L、NaHCO3 0.4g/L、MgCl2·6H2O 0.015g/L、MgSO4·7H2O 0.05g/L、KH2PO4
0.06g/L、Na2HPO4·12H2OO 0.06g/L, glucose 2g/L, urea 1.5g/L, gram positive bacterial cell fragment
0.002g/L and balance deionized water.
Preferably, the gram positive bacterial cell fragment is by bifidobacterium cells fragment and lactobacillus cell fragment
By 1:1 weight is than composition.
Preferably, the biomimetic type gynaecologic washing lotion also includes vagina renovation agent, and the vagina renovation agent is in the artificial mould
It is 0.1~2g/L to intend the content in vaginal secretion, and the vagina renovation agent is selected from water solubility VE, NMF and dissociates
One or more in amino acid.
Preferably, the vagina renovation agent presses 1 by water-soluble VE, NMF and free amino acid:0.5~1:1
~2 weight is than composition.
Preferably, the vagina renovation agent presses 1 by water-soluble VE, NMF and free amino acid:0.5:1 weight
Amount is than composition.
Preferably, the free amino acid is selected from the one kind or several in glycine, alanine, asparatate and serine
Kind.
Correspondingly, present invention also offers the preparation method of above-mentioned biomimetic type gynaecologic washing lotion, comprise the following steps：
A 5~10g/L of NaCl, 0.3~0.5g/L of KCl, CaCl) are taken20.1~0.2g, NaHCO30.3~0.45g/L,
MgCl2·6H20.006~0.015g/L of O, MgSO4·7H20.04~0.08g/L of O, KH2PO40.05~0.08g/L,
Na2HPO4·12H20.05~0.08g/L of O, 0.1~2.5g/L of glucose, 0.5~3g/L of urea and gram-positive bacterium
0.001~0.003g/L of cell fragment is dissolved in deionized water, is uniformly mixed, constant volume, and regulation pH is 3.3~4.8, is obtained final product
Manual simulation's vaginal secretion；
B) take 0.05~0.15g/L xanthans to be dissolved in deionized water, stir, be configured to xanthan gum solution, plus
Enter 5~10.0g/L house fly antibiotic peptides, continue to stir 10~15min, add 0.1~10.0g/L xylo-oligosaccharides, stirring obtains one and mixes
Close liquid；
C) step A is added toward above-mentioned mixed liquor) gained manual simulation's vaginal secretion, to stir, homogenization is obtained final product bionical
Type gynaecologic washing lotion.
Preferably, the step B) in be additionally included in addition house fly antibiotic peptide after add vagina renovation agent.
The present invention to the full extent simulate human vagina's juice composition, on the basis of artificial body fluid add urea and
Gram positive bacterial cell fragment, is preferably added to bifidobacterium cells fragment and lactobacillus cell fragment, and it can induce the moon
The generation of Bifidobacterium and Bacillus acidi lactici in road, adds xylo-oligosaccharide specifically to promote beneficial bacterium Bacillus acidi lactici and the dry bacterium of bifid
Amount reproduction, the Bacillus acidi lactici of breeding and Bifidobacterium can be colonized by occupy-place, competition nutrition, secretion H2O2With bacteriocin etc.
Antibacterial substance and suppress in vagina and enteron aisle in middle pathogenic microorganisms growth and breeding, additionally by Bacillus acidi lactici and bifid
Bacillus produces a large amount of SCFA such as acetic acid, propionic acid and butyric acid etc. to adjust the acidity of vagina, two using xylo-oligosaccharide fermentation
Person's Synergistic, can be quick, active balance vaginal flora and regulation vagina acidity.
Because antibacterial peptide is under high salt concentration, anti-microbe ability can be obviously reduced, it is contemplated that manual simulation's vaginal secretion
The hypersaline environment of liquid, it is found by the applicant that house fly antibiotic peptide remains to maintain excellent bioactivity in high salt concentration, and its heat is steady
It is qualitative good, beneficial to the carrying out of subsequent high temperature disinfecting action；Because washing lotion is short in the intravaginal residence time, antibacterial peptide action time
It is short, therefore need to repeat lavation vagina in order to reach preferable antibacterial effect, when using every time, it is found by the applicant that first by xanthan
Glue is coupled with antibacterial peptide, using the bioadhesive of xanthans itself, can be attached on mucous membrane and cell for a long time, and extension is anti-
The action time of bacterium peptide, and then lavation number of times is reduced, both cooperate with the fungistatic effect that increased washing lotion.
In view of the damage that vaginitis is caused to vagina, it is aided with water-soluble VE, NMF and free amino acid, swims
Isolated amino acid has powerful moisture-retaining capacity, and it can keep the moisture of vagina inner skin, makes vagina skin lubrication, flexible.
In sum, the present invention greatly improves antibacterial effect while reducing lavation number of times using the coupling of house fly antibiotic peptide xanthans,
Cooperate with xylo-oligosaccharide strong again using the generation of gram positive bacterial cell fragment induction intravaginal Bifidobacterium and Bacillus acidi lactici
The function of big regulation vaginal flora and vagina acidity, is finally aided with the solvent close with human vagina's secretory component and to vagina
Composition with repair, each component compatibility rationally, is made a distinction between the important and the lesser one, and composition one has sterilized, balance vaginal flora, vagina concurrently
The stabilising system of acidity and reparation vaginal injury function.
Compared with prior art, bionical gynaecologic washing lotion of the invention has the advantage that：
1) biomimetic type gynaecologic washing lotion of the present invention uses Bionic Design, on vaginal microenvironment and vagina physiological equilibrium influence compared with
It is small, will not make cell produce drug resistance, its compared with existing gynaecologic washing lotion, with prominent bactericidal effect, to bacillary the moon
Road inflammation, monilial vaginitis, trichomonas vaginitis and Combination vaginitis are respectively provided with significant therapeutic effect.
2) present invention greatly improves antibacterial effect while reducing lavation time using the coupling of house fly antibiotic peptide xanthans
Number, xylo-oligosaccharide is cooperateed with using the generation of gram positive bacterial cell fragment induction intravaginal Bifidobacterium and Bacillus acidi lactici again
The function of powerful regulation vaginal flora and vagina acidity, is finally aided with the solvent close with human vagina's secretory component and to the moon
Road has the composition of repair, and each component compatibility rationally, is made a distinction between the important and the lesser one, and composition one has sterilized, balance vaginal flora, the moon concurrently
The stabilising system of road acidity and reparation vaginal injury function.
3) present component safety non-toxic, preparation method is simple.
Specific embodiment：
Below by way of the description of specific embodiment, the invention will be further described, but this is not to limit of the invention
System, those skilled in the art's basic thought of the invention, various modifications may be made or improves, but without departing from this
The basic thought of invention, within the scope of the present invention.
The preparation method bibliography of present inventor's diptercin：Zhou Yiwen, Yin Yibing, apply and plant the house fly antibiotic peptides such as light
Primary Study [J] China antibiotic magazine of antibacterial activity and antibacterial mechanisms, 2004,5 (29) remaining each raw material sources are in city
Sell, such as antibacterial peptide derives from Hai Na rivers medicine company in comparative example 1.
Embodiment 1, a kind of biomimetic type gynaecologic washing lotion
The biomimetic type gynaecologic washing lotion of the present embodiment 1 is composed of the following components：House fly antibiotic peptide 0.1g, xylo-oligosaccharide 6.0g, Huang
Virgin rubber 0.1g, NaCl 8.0g, KCl 0.45g, CaCl2 0.15g、NaHCO3 0.4g、MgCl2·6H2O 0.015g、MgSO4·
7H2O 0.05g、KH2PO4 0.06g、Na2HPO4·12H2O 0.06g, glucose 1.0g, urea 1.5g, gram-positive bacterium
Cell fragment 0.002g, 1L is settled to deionized water, wherein, the growth factor is by recombinant human epidermal growth factor and restructuring
Human alkaline fibroblast growth factor presses 1:, than composition, the gram positive bacterial cell fragment is by bifid bar for 1 weight
Bacterium cell fragment and lactobacillus cell fragment press 1:1 weight is than composition.
Preparation method：
A) by NaCl, KCl, CaCl2、NaHCO3、MgCl2·6H2O、MgSO4·7H2O、KH2PO4、Na2HPO4·12H2O、
Urea, gram positive bacterial cell fragment and glucose are dissolved in 800ml deionized waters, are uniformly mixed, and are added water to
1000ml, regulation pH is 3.4, obtains final product manual simulation's vaginal secretion；
B) take xanthans to be dissolved in deionized water, stir, be configured to xanthan gum solution, add house fly antibiotic peptide,
Continue to stir 10min, add xylo-oligosaccharide, stirring obtains a mixed liquor；
C) step A is added toward above-mentioned mixed liquor) gained manual simulation's vaginal secretion, to stir, homogenization is obtained final product bionical
Type gynaecologic washing lotion.
Embodiment 2, a kind of biomimetic type gynaecologic washing lotion
The biomimetic type gynaecologic washing lotion of the present embodiment 2 is composed of the following components：House fly antibiotic peptide 0.1g, xylo-oligosaccharide 6.0g, Huang
Virgin rubber 0.1g, NaCl 8.0g, KCl 0.45g, CaCl2 0.15g、NaHCO3 0.4g、MgCl2·6H2O 0.015g、MgSO4·
7H2O 0.05g、KH2PO4 0.06g、Na2HPO4·12H2O 0.06g, glucose 1.0g, urea 1.5g, gram-positive bacterium
Cell fragment 0.002g, water solubility VE0.4g, NMF 0.2g and free amino acid 0.4g, are settled to deionized water
1L, wherein, the growth factor presses 1 by recombinant human epidermal growth factor and recombination human basic fibroblast growth factor:1
Weight presses 1 than composition, the free amino acid by glycine, alanine, asparatate and serine:1:1:1 weight
Than composition, the gram positive bacterial cell fragment presses 1 by bifidobacterium cells fragment and lactobacillus cell fragment:1
Weight is than composition.
Preparation method reference implementation example 1.
Embodiment 3, a kind of biomimetic type gynaecologic washing lotion
The biomimetic type gynaecologic washing lotion of the present embodiment 3 is composed of the following components：House fly antibiotic peptide 0.2g, xylo-oligosaccharide 5.0g, Huang
Virgin rubber 0.1g, NaCl 8.0g, KCl 0.45g, CaCl2 0.15g、NaHCO3 0.4g、MgCl2·6H2O 0.015g、MgSO4·
7H2O 0.05g、KH2PO4 0.06g、Na2HPO4·12H2O 0.06g, glucose 1.0g, urea 1.5g, gram-positive bacterium
Cell fragment 0.001g, water solubility VE 0.4g, NMF 0.2g and free amino acid 0.4g, use deionized water constant volume
To 1L, wherein, the growth factor presses 1 by recombinant human epidermal growth factor and recombination human basic fibroblast growth factor:1
Weight than composition, the free amino acid by glycine, alanine, asparatate and serine press 1:1:1:1 weight
Amount presses 1 than composition, the gram positive bacterial cell fragment by bifidobacterium cells fragment and lactobacillus cell fragment:1
Weight than composition.
Comparative example 1, a kind of biomimetic type gynaecologic washing lotion
Remove component gram positive bacterial cell fragment, remaining component and its consumption such as embodiment 2.
Preparation method reference implementation example 2.
Comparative example 2, a kind of biomimetic type gynaecologic washing lotion
Remove component urea, remaining component and its consumption such as embodiment 2.
Preparation method reference implementation example 2.
Comparative example 3, a kind of biomimetic type gynaecologic washing lotion
The biomimetic type gynaecologic washing lotion of this comparative example 3 is composed of the following components：House fly antibiotic peptide 0.1g, xylo-oligosaccharide 6.0g, Huang
Virgin rubber 0.2g, NaCl 8.0g, KCl 0.45g, CaCl2 0.15g、NaHCO3 0.4g、MgCl2·6H2O 0.015g、MgSO4·
7H2O 0.05g、KH2PO4 0.06g、Na2HPO4·12H2O 0.06g, glucose 1.0g, urea 1.5g, gram-positive bacterium
Cell fragment 0.002g, water solubility VE0.4g, NMF 0.2g and free amino acid 0.4g, are settled to deionized water
1L, wherein, the growth factor presses 1 by recombinant human epidermal growth factor and recombination human basic fibroblast growth factor:1
Weight presses 1 than composition, the free amino acid by glycine, alanine, asparatate and serine:1:1:1 weight
Than composition, the gram positive bacterial cell fragment presses 1 by bifidobacterium cells fragment and lactobacillus cell fragment:1
Weight is than composition.
Preparation method reference implementation example 2.
Comparative example 3 and the difference of embodiment 2 are the consumption that increased xanthans.
Test example one, stability test
1st, trial target：The embodiment of the present invention 1~3 and the biomimetic type gynaecologic washing lotion of comparative example 1~3.
2nd, test method：By above-mentioned each group washing lotion, constant temperature is placed two weeks at 45 DEG C, then observes each gynaecologic washing lotion proterties
Change, test result see the table below 1.
The stability test result of table 1
As shown in Table 1, embodiment 1~3 and the biomimetic type washing lotion of comparative example 1~2 constant temperature at through 45 DEG C place two weeks
There is not muddiness, lamination, with good stability, and the constant temperature at 45 DEG C of comparative example 3 has muddy product after placing two weeks
Raw, its stability is not so good as remaining each group.
Performance test
Experiment 1, gynaecologic washing lotion of the present invention to gonococcus, staphylococcus aureus, Candida albicans bactericidal effect
1.1 trial targets：The embodiment of the present invention 1~3 and the biomimetic type gynaecologic washing lotion of comparative example 1~2.
1.2 test methods：
(1) aseptic filter paper piece is taken, the every embodiment of the present invention 1~3 and the gynaecologic washing lotion of comparative example 1~2 that 20 μ l are added dropwise will
Filter paper is lain against in sterilized petri dishes, is uncapped, standby after spontaneously drying at room temperature；
(2) concentration is 7 × 105The gonococcus of cfu/ml, staphylococcus aureus, Candida albicans bacteria suspension it is each
100 μ l move to nutrient agar planar surface, and uniform application is covered, cultivated at room temperature；
(3) filter paper is placed on the above-mentioned nutrient agar flat board for scribbling different strain, the training of each nutrient agar
Support be placed with base flat board 5 respectively drop there is embodiment 1~3 and the cleaning fluid for gynecology filter paper of comparative example 1~2,1 drop to have sterilized water
Filter paper (blank group), at a distance of more than 20mm between each filter paper center, and with more than the border 10mm of flat board.Post
Afterwards with the light press filtration scraps of paper of tweezers, it is adjacent to, covered；3 repetitions are set per test group, each nutrient agar flat board is placed in
Cultivated 24 hours in 37 DEG C of insulating boxs, observe the antibacterial circle diameter size of each group cleaning fluid, take 3 cell means, statistics is shown in
Table 2 below.
The bacteriostasis property test result of table 2
As shown in Table 2,1~3 group of embodiment is respectively provided with to staphylococcus aureus, staphylococcus aureus and gonococcus
Excellent killing effect, particularly 2 groups of embodiment；Compared with 2 groups of embodiment, it is to three kinds of killings of germ for comparative example 1 and 2 groups
Effect decreases.
Trichomonas vaginalis experiment is killed in experiment 2, gynaecologic washing lotion of the present invention
2.1 trial drugs：The embodiment of the present invention 1~3 and the biomimetic type gynaecologic washing lotion of comparative example 1~2 are taken, trial drug is high
After pressure sterilizing, the aseptic doubling dilution of difference, highest dilution is 1:16, embodiment 1~3 and the dilution of comparative example 1~2 are obtained, point
Do not take in the above-mentioned dilution addition test tubes of 2ml, mark is good standby.
2.2 supply test worm kind：Trichomonas vaginalis, the vagina hair drop provided by clinical hospitals gynemetrics of Chinese Medical Sciences University the 3rd
The 30 worms strain being separately cultured in worm patient's vaginal fluid.
2.3 culture mediums：Trichomonas vaginalis culture medium, matches somebody with somebody with reference to clinical medical inspection handbook (publication of Jilin Science Press)
Hepar-peptone-glucose medium processed.
2.4 worm kind cultures：Take above-mentioned trichomonas vaginalis and be inoculated in culture medium, per the passage of 3d transferred speciess, stabilization 3 generations of culture are carried out
Experiment.
2.5 test methods：Take respectively during the nutrient solution 0.05ml after Secondary Culture 48h adds above-mentioned dilution test tube, gently
Jog is even, then toward aseptic hepar-peptone-glucose medium 8ml is added in above-mentioned test tube, 37 DEG C of incubator cultures is placed in, every 24h suction pipes
Bottom culture microscopy, even inspection three days, observe polypide survival condition after light liquid is acted on and count the trichomonad death rate, statistics knot respectively
Really, such as table 3.
The result of the test of table 3
As shown in Table 3, when trial drug dilution factor is 1:When 1, each group has preferable killing effect to pubes trichomonad, kills
Trichomonad effect of going out is ordered as from high to low：The ＞ comparative examples 1 of 1 ＞ comparative examples of embodiment 2 ＞ embodiments, 3 ＞ embodiments 2；Work as investigational agent
Thing dilution factor reaches 1:When 16, embodiment 1~3 has the trichomonad of more than half to be killed after dosing 72h, still, and comparative example 1~
2 after dosing 72h the trichomonad death rate be only 32% and 38%, this explanation 1~3 pair of pubes trichomonad of the embodiment of the present invention have it is excellent
Killing effect, wherein it is most notable to have been carried out the killing effect of example 2.
Clinical test
1.1 clinical datas
The voluntary patient of vagina 560 that in May, 2012~2014 year July goes to a doctor in institute of traditional Chinese medicine of Zixing City of Hunan Province, wherein
Bacterial vaginitis 160, monilial vaginitis 200, trichomonas vaginitis 80, Combination vaginitis 120.Patient
21~62 years old age, average age 34.6 years old.Medical patient is with different degrees of pruritus vulvue burn feeling, vaginal fluid
Increase, waist abdomen pain, leucorrhea increasing proterties change etc. symptom.
1.2 packets and treatment method
All types of vaginitis patients are divided into the treatment group of embodiment 1~3 and routine medication control group, treatment group at random
The gynaecologic washing lotion lavation vulva of example 1~3, vagina 5min are applied in receiving, and once a day, 7d is a course for the treatment of.Monilial vagina in control group
After inflammation is with 3% sodium bicarbonate solution rinsing vulva, vagina, 200mg Gyno-Daktarins are placed in intravaginal；Bacterial vaginitis with
After 1% compound iodine rinsing vulva, vagina, 500mg Flagyl suppositories are placed in intravaginal；Trichomonas vaginitis is rushed with 0.5% acetic acid
After washing vulva, vagina, 400mg metronidazole suppositories are placed in intravaginal；Combination vaginitis then uses drug combination.All treatments are equal
Once a day, continuous 7d is a course for the treatment of.Respectively before the treatment, 7d checks patient clinical symptom, sign and the moon after the course for the treatment of terminates
The change of road secretion.Observation index includes：Vulva is uncomfortable, leukorrhea amount, smell and proterties, and vulva/vagina is congested, oedema, cloudy
Road cleannes, pH value, vagina etiological examination etc..
1.3 curative effect determinate standards
4 grades of standards are divided into according to patient symptom, sign and vaginal fluid testing result.1. cure：Through treating clinical condition
Shape and Signs are wholly absent, and vaginal fluid etiological examination is negative.2. it is effective：Substantially mitigate through treating clinical symptoms, sign
It is clearly better, but is not wholly absent, vaginal fluid etiological examination is negative.3. it is effective：Have through treating clinical symptoms and sign
Improved, vaginal fluid etiological examination is negative or positive.3. it is invalid：Even add without improvement through treating clinical symptoms and sign
Weight, vaginal fluid etiological examination is the positive.To cure+effective patient's number of cases calculating total effective rate.
2. result is as follows
The bacterial vaginitis therapeutic effect of table 4
The monilial vaginitis therapeutic effect of table 5
The trichomonas vaginitis therapeutic effect of table 6
The Combination vaginitis treatment effect of table 7
Consolidated statement 4~7 understand, through the above-mentioned 4 kinds of vaginitis of 1~3 group for the treatment of of embodiment after, failing to respond to any medical treatment does not occur in patient
Situation, and through the gynaecologic washing lotion of the embodiment of the present invention 1~3 cure patient be discontinued after no relapse；Wherein, 1~3 group of embodiment
The cure rate for the treatment of bacterial vaginitis, monilial vaginitis, trichomonas vaginitis and Combination vaginitis reaches
More than 80%, total effective rate reaches more than 90.0%, significantly larger than control group；Wherein, it is different types of with 2 groups of treatments of embodiment
Vaginitis best results, and 2 groups for the treatment of trichomonal vaginitis total effective rates of embodiment are up to 100%, this explanation embodiment of the present invention 1
~3 pairs of bacterial vaginitis, monilial vaginitis, trichomonas vaginitis and Combination vaginitis are respectively provided with significant treatment
Effect.
Claims (8)
1. a kind of biomimetic type gynaecologic washing lotion, it is characterised in that including house fly antibiotic peptide, xylo-oligosaccharide, xanthans and pH be 3.3
~4.8 manual simulation's vaginal secretion, the house fly antibiotic peptide, xylo-oligosaccharide and xanthans are in manual simulation's vaginal secretion
Content in liquid is respectively 0.1~10.0g/L, 5~10.0g/L and 0.05~0.15g/L；Manual simulation's vaginal secretion
It is composed of the following components：5~10g/L of NaCl, 0.3~0.5g/L of KCl, CaCl20.1~0.2g/L, NaHCO30.3~
0.45g/L、MgCl2·6H20.006~0.015g/L of O, MgSO4·7 H20.04~0.08g/L of O, KH2PO40.05~
0.08g/L、Na2HPO4·12 H20.05~0.08g/L of O, 0.1~2.5g/L of glucose, 0.5~3g/L of urea, gram sun
Property 0.001~0.003g/L of bacterial cellular debris and balance deionized water；The gram positive bacterial cell fragment is by double
Discrimination bacilli-cell fragment and lactobacillus cell fragment press 1:1 weight is than composition.
2. biomimetic type gynaecologic washing lotion as claimed in claim 1, it is characterised in that the house fly antibiotic peptide, xylo-oligosaccharide and
Content of the xanthans in manual simulation's vaginal secretion is respectively 0.1g/L, 6.0g/L and 0.1g/L.
3. biomimetic type gynaecologic washing lotion as claimed in claim 1, it is characterised in that manual simulation's vaginal secretion is by following
Component is constituted：NaCl 8.0g/L、KCl 0.45g/L、CaCl2 0.15g/L、NaHCO3 0.4g/L、MgCl2·6H2O
0.015g/L、MgSO4·7H2O 0.05g/L、KH2PO4 0.06g/L、Na2HPO4·12H2O 0.06g/L, glucose 2g/L,
Urea 1.5g/L, gram positive bacterial cell fragment 0.002g/L and balance deionized water.
4. biomimetic type gynaecologic washing lotion as claimed in claim 1, it is characterised in that the biomimetic type gynaecologic washing lotion also includes vagina
Renovation agent, content of the vagina renovation agent in manual simulation's vaginal secretion is 0.1~2g/L, the vagina reparation
Agent is selected from one or more in water solubility VE, NMF and free amino acid.
5. biomimetic type gynaecologic washing lotion as claimed in claim 4, it is characterised in that the vagina renovation agent is by water-soluble VE, day
Right moisturizing factor and free amino acid press 1:0.5~1:1~2 weight is than composition.
6. the biomimetic type gynaecologic washing lotion as described in claim 4 or 5, it is characterised in that the free amino acid be selected from glycine,
One or more in alanine, asparatate and serine.
7. a kind of preparation method for preparing biomimetic type gynaecologic washing lotion as claimed in claim 1, it is characterised in that including following step
Suddenly：
A 5~10g/L of NaCl, 0.3~0.5g/L of KCl, CaCl) are taken20.1~0.2g, NaHCO30.3~0.45g/L,
MgCl2·6H20.006~0.015g/L of O, MgSO4·7H20.04~0.08g/L of O, KH2PO40.05~0.08g/L,
Na2HPO4·12H20.05~0.08g/L of O, 0.1~2.5g/L of glucose, 0.5~3g/L of urea and gram-positive bacterium
0.001~0.003g/L of cell fragment is dissolved in deionized water, is uniformly mixed, constant volume, and regulation pH is 3.3~4.8, is obtained final product
Manual simulation's vaginal secretion；
B) take 0.05~0.15g/L xanthans to be dissolved in deionized water, stir, be configured to xanthan gum solution, add 5~
10.0g/L house fly antibiotic peptides, continue to stir 10~15min, add 0.1~10.0g/L xylo-oligosaccharides, and stirring obtains a mixed liquor；
C) step A is added toward above-mentioned mixed liquor) gained manual simulation's vaginal secretion, to stir, homogenization obtains final product biomimetic type woman
Section's washing lotion.
8. the preparation method of biomimetic type gynaecologic washing lotion as claimed in claim 7, it is characterised in that the step B) in be additionally included in
Vagina renovation agent is added after adding house fly antibiotic peptide.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610316286.3A CN105999224B (en) | 2016-05-11 | 2016-05-11 | A kind of biomimetic type gynaecologic washing lotion and preparation method thereof |
| PCT/CN2016/097615 WO2017193509A1 (en) | 2016-05-11 | 2016-08-31 | Bionic gynecological lotion and preparation method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610316286.3A CN105999224B (en) | 2016-05-11 | 2016-05-11 | A kind of biomimetic type gynaecologic washing lotion and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105999224A CN105999224A (en) | 2016-10-12 |
| CN105999224B true CN105999224B (en) | 2017-06-16 |
Family
ID=57099464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610316286.3A Active CN105999224B (en) | 2016-05-11 | 2016-05-11 | A kind of biomimetic type gynaecologic washing lotion and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN105999224B (en) |
| WO (1) | WO2017193509A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045277A (en) * | 2018-09-07 | 2018-12-21 | 北京肽康生物科技有限公司 | A kind of molten antibacterial peptide combinations of AMPs-O oil and its application |
| CN109395062B (en) * | 2018-12-29 | 2021-12-14 | 广州肽然生物科技有限公司 | Female pudendum sterilization care solution |
| CN119405789B (en) * | 2024-10-21 | 2025-06-20 | 广州斐博生物科技有限公司 | Gynecological vaginal mucosa repair gel and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1218622A (en) * | 1997-12-05 | 1999-06-09 | 王树亮 | Antibiotic bactericide and its producing technology |
| CN1557288A (en) * | 2004-02-10 | 2004-12-29 | 周世兰 | Lactic acid , glycerin formulation for female vagina acidity, humidity improvement |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1264581A (en) * | 1999-02-22 | 2000-08-30 | 曾忠铭 | Medicine for reducing vaginal acidity and its usage |
| US20030229335A1 (en) * | 2002-04-30 | 2003-12-11 | Payne Richard Grady | Apparatus and method for delivery of constrained beneficial bacteria to the vaginal tract |
| CN101502525B (en) * | 2008-02-04 | 2011-07-20 | 山东省生物药物研究院 | Application of low-polyxylose in preparing product for preventing and treating colpitis |
| WO2010002241A1 (en) * | 2008-06-30 | 2010-01-07 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
| CN102755260B (en) * | 2012-07-20 | 2013-09-25 | 姚春宝 | Female pudendum cleaning health-care fluid and preparation method thereof |
| CN103126917B (en) * | 2013-02-27 | 2014-05-28 | 广州市科玮生物技术有限公司 | Bionic gynecologic care solution and its preparation method |
-
2016
- 2016-05-11 CN CN201610316286.3A patent/CN105999224B/en active Active
- 2016-08-31 WO PCT/CN2016/097615 patent/WO2017193509A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1218622A (en) * | 1997-12-05 | 1999-06-09 | 王树亮 | Antibiotic bactericide and its producing technology |
| CN1557288A (en) * | 2004-02-10 | 2004-12-29 | 周世兰 | Lactic acid , glycerin formulation for female vagina acidity, humidity improvement |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017193509A1 (en) | 2017-11-16 |
| CN105999224A (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108452295A (en) | A kind of compact gel and preparation method antibacterial, that adjust microecological balance | |
| CN107802825A (en) | A kind of Traditional Chinese medicine gel composition antibacterial for vaginal mucosa | |
| CN111481498A (en) | A kind of antibacterial gel for regulating female vaginal microecological balance and preparation method thereof | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN107243017A (en) | A kind of antibacterial balance gynecological gel and preparation method thereof | |
| CN108158995A (en) | A kind of gynaecology's anti-bacteria foaming agent containing chitosan and preparation method thereof | |
| CN101543658B (en) | Cervical cap for preventing and treating cervical erosion and preparation method thereof | |
| CN105999224B (en) | A kind of biomimetic type gynaecologic washing lotion and preparation method thereof | |
| CN109771368A (en) | A kind of bacteriostatic gel and preparation method thereof | |
| CN111449973A (en) | Foaming agent for restoring microecological balance of female vagina and preparation method thereof | |
| CN106957811A (en) | Application of the form lactobacillus with bacteriostasis with Chinese medicine compound prescription and its in treatment gynaecological imflammation | |
| CN106580871A (en) | Vaginal gel and preparation method thereof | |
| CN109985069A (en) | Probiotic composition and application thereof | |
| CN113082050A (en) | Temperature-sensitive gel for gynecology and preparation method thereof | |
| CN104306324A (en) | Medical collagen gel and preparation method thereof | |
| CN101797269B (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN109078069A (en) | Vaginal mucosa antibacterial gel and preparation method thereof | |
| CN111973551A (en) | Mussel mucin antibacterial gel and preparation method thereof | |
| CN115770195B (en) | Stable acne-removing composition and preparation method thereof | |
| CN105168498A (en) | Compound disinfectant liquid and preparation method thereof | |
| Vanwersch | Crocodile bite injury in southern Malawi | |
| CN101757119B (en) | Medicine composition for treating vaginitis as well as gel and preparation method thereof | |
| CN104083565A (en) | Bedsore skin-activating ointment and application thereof | |
| CN108606978A (en) | A kind of milk cow hoof liquid formulation and preparation method thereof | |
| CN107551090A (en) | One kind, which is nourished, repairs gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |